adami pharmaceut corpor admp hold zimhi get downgrad share hold analyst jason
 buy pt investor day demonstr justif premium valuat rais pt
reiter buy rate analyst michael diana full summari
nutanix inc buy pt result guidanc impli bottom y/i trajectori resumpt hypergrowth
first inc fsfg buy pt strong driven robust mortgag bank activ
dave buster entertain inc buy pt reiter buy pt ahead result prepar
wow return double-digit ep growth analyst stephen anderson full summari
appli dna scienc inc apdn buy pt custom board linear dna could follow also
watch ctc platform analyst jason mccarthi ph full summari
cytosorb corpor buy pt speed bump refresh focu revenu growth europ
matina biopharma hold inc mtnb buy pt medicin compani goe novarti activ
corpor event call maxim salesperson inform
aptorum group ltd apm ndr nyc ceo dr ian huan presid execut director darren lui senior
medicenna corp mdna cover mccarthi ndr nyc ceo fahar merchant phd cfo
cerecor inc cover mccarthi institut client dinner nyc ceo simon pedder jame
harrel cfo miller vice-president head discoveri stephen thoma wed dec
nephro inc neph cover vendetti ndr nyc ceo daron evan tue dec
cover sullivan ndr philadelphia ceo batrack mon-tu dec
cover sullivan ndr baltimor ceo batrack tue-w dec
inc cover sullivan ndr nyc ceo dickerson wright wed dec
graham corpor cover sullivan ndr st loui cfo jeffrey glajch thu dec
graham corpor cover sullivan ndr kansa citi cfo jeffrey glajch fri dec
nutanix inc cover chokshi ndr san francisco cfo duston mon dec
turtl beach corp hear cover chokshi ndr nyc ceo juergen stark thu dec
pure storag inc cover chokshi ndr nyc execut tbd tue
pure storag inc cover chokshi ndr boston execut tbd wed
guidanc in-lin consensu
bill guidanc drive valuat de minimi risk view
in-lin guidanc reiter buy rate price target
product revenu miss obfusc on-going strong bill growth
yesterday market close report oct revenu
y/i q/q guidanc rang well
consensu estim product revenu y/i
q/q miss consensu estim though bill
y/i ahead high-end guidanc rang bill
beat attest manag explan product miss attribut
compens structur asymmetr incentiv next-gener secur
product prisma cloud sale result servic subscript mainten
revenu y/i q/q consensu
continu trend impress y/i growth trajectori record past
four quarter servic revenu upsid larg driven subscript revenu
y/i slight acceler prior three qs y/i growth
q/q mainten revenu y/i q/q
gm y/i q/q due lower servic gm result
higher host data manag cost relat panw next-gen secur
guidanc in-lin consensu manag provid in-lin
revenu guidanc rang bill guidanc
in-lin estim bracket consensu non-gaap
ep guidanc rang includ increment expens
relat propos aporeto acquisit consensu midpoint
impli increment increas opex
bill guidanc drive valuat de minimi risk view
per figur basi bill guidanc rais consist
beat fcf/revenu guidanc exclud impact
announc aporeto acquisit believ manag explan
sale incent larg contribut product revenu disappoint
believ salesforc gravit toward next-gen product may also
demand-driven custom move consumption-bas model capex-
base model and/or competitor-driven better compet zs
nr result reduc product revenu estim de-risk potenti
product revenu miss non-consequenti valuat rais servic
 defer revenu estim leav forward bill estim larg
unchang respect potenti shift next-gen secur offer
zscaler-driven note still post impress sale product per
metric track best-in-class amongst coverag univers
per juli note explor technolog basi zs vs continu
believ offer custom superior cyber-secur postur due
greater breadth integr best-in-class cybersecur offer includ next-
firewal also note potenti neg interpret slow
hardwar instal base growth rate limit softwar attach take
account de-coupl subscript bill hardwar result panw
next-gen secur offer cortex prisma deploy complet independ
compani next-gen firewal hardwar
in-lin guidanc reiter buy rate price target
manag reiter revenu guidanc rang
increas bill guidanc account
bill beat result slightli lower termin period
revenu estim estim
assum unchang margin result unchang dcf-deriv
price target long-term estim also assum unchang
 product ratio compar achiev
achiev termin period revenu estim
compar opportun laid address market
click full note
result guidanc impli bottom y/i trajectori
resumpt hypergrowth stage rais pt
softwar support bill modestli consensu
midpoint januari guidanc data point impli y/i trajectori
bottom juli
guidanc unchang impli acceler hyper-growth
maintain buy rate rais price target
remain well-posit subsum oper profit pool consist
multipl infrastructur softwar segment view
softwar support bill modestli consensu yesterday
market close report oct softwar support sw bill
y/i acceler prior quarter flat y/i q/q beat
estim believ consensu estim product
gm y/i q/q hardwar pass-through revenu
declin q/q y/i result overal gm opex
y/i q/q in-lin guidanc
result top-lin upsid translat loss per share slightli narrow
guidanc result give us increas confid octob
prior assert deterior sale product sinc due
narrow gap product differenti rather aggress
market tactic taken underspend ntnx-lead gener
would expos manag also disclos first time annual contract valu plu
renew y/i manag expect
acceler y/i growth jan
midpoint januari guidanc data point impli y/i trajectori
bottom juli manag provid jan softwar
support sw bill guidanc rang y/i q/
 midpoint impli consensu estim
acceler y/i growth flat believ one
major driver on-going improv y/i softwar support trajectori
sale team abil drive adopt adjac infrastructur softwar offer
hyper-converg infrastructur non-cor offer increas
deal ltm basi ltm basi april continu
expect xi cluster major acceler nonhci softwar adopt
enabl on-demand flex workload on-premis resourc off-premis
resourc expect ga
guidanc unchang impli acceler hyper-growth
manag reiter softwar support sw bill guidanc
y/i /- impli acceler y/i growth profil
y/i growth previous disclos
manag note fiscal year guidanc includ impact shift
life devic averag lifetim year term-bas licens averag durat
year neg impact top-line result
maintain buy rate rais price target
remain well-posit subsum oper profit pool consist
multipl infrastructur softwar segment view continu believ
nutanix remain attract price enterpris valu perspect
well-posit subsum oper profit pool consist
server storag oper system hypervisor cloud manag softwar
system manag softwar dcf-mechan perspect long-
term oper margin estim product note
per cfo duston william present see slide page figur
march note transit zero-growth compani new
custom dcf termin period oper margin well
dcf-base project note even impli long-
term oper margin appear conserv rel msft- nr
oper margin room improv nr oper
oper margin base updat guidanc lead us rais
opex get compound increas sale dcf termin
period rais termin period revenu estim
thu termin period main driver
increas price target
click full note
reiter buy pt ahead result prepar
wow return double-digit ep growth
reiter buy rate price target dave buster
ahead earli decemb releas octob result
maintain ep estim vs street though lower
januari ep estim vs street
nevertheless still model mid-teen percent ep growth ahead reflect
revis ep estim vs street
ep estim vs street expect
instal wall earli catalyst
maintain ep estim though lower januari
ep estim septemb compani post-
earn report caution potenti soft result given difficult
y/i comparison amus busi ttm sale success
jurass world vr attract broader challeng food beverag
busi ttm sale amus traffic
attach purchas expect limit impact hurrican dorian given
locat florida thu reduc blend comp estim
vs street howev reduc blend comp
estim vs street believ lacklust box offic
return termin dark translat modest perform
play exclus virtual realiti vr movi tie-in attract launch novemb
even expect vr game continu support slightli higher margin
non-vr game
nevertheless still model mid-teen percent ep growth ahead reflect
revis ep estim ep estim
revis outlook assum full-year comp forecast
expect catalyst
arriv earli instal wall upgrad video
packag bar area estim locat base
prior manag comment believ base check locat
wall comp locat return low-to-mid-single-
digit posit base manag found dalla flagship expect
system-wid instal help mitig concern play sluggish casual
dining/f busi although manag provid guidanc wall
instal beyond expect acceler instal schedul
continu result heighten depreci expens expect
mid-teen ep growth continu support margin expans share
also believ presenc activist keep floor play share
price august activist hedg fund hg vora disclos posit
share fourth-largest holder although hg vora yet discuss plan
fund histori activ broader hospit industri
share price nearli may high contend
valuat becom compel share trade
revis ep estim revis ep estim
multipl well play post-ipo averag forward price-to-earnings ratio
arriv unchang price target multipli revis forward
price-to-earnings multipl target revis ep estim
prior ep estim price target also correspond forward
ev/ebitda ratio use base valuat year play
post-ipo averag
click full note
investor day demonstr justif premium
valuat rais pt reiter buy rate
investor day novemb demonstr deserv premium
compani price-to-earnings ratio suppos reflect growth prospect
risk bank main risk credit risk unusu -- uniqu
growth bank excel credit qualiti lower risk
rais price target new price target
equat ep estim versu previous
deserv premium high-qual smid-cap bank
disrupt superior client servic use entir all-day investor day
novemb drive home very-simple-to-articul very-difficult-to-execut
strategi compani almost bank challeng formul
elev pitch challeng investor day fill whole day talk
better servic servic retain exist client account
new busi prompt referr new busi
view succeed show superior client servic drive growth
demograph franchis favor strategi strategi
work best upscal urban market focus actual
coastal upscal urban market especi san francisco bay area home
market dynam nation arguabl world
past year exist
strategi implement chang compani
found ceo jim herbert gateway product new client young
profession jumbo mortgag millenni student loan refi
way jumbo mortgag wherea technolog rudimentari
competit megabank mantra high tech empow
replac high touch servic wherea wealth manag busi
bank cross-sel line busi huge contributor inde wealth
manag univers regard desir add-on upscal bank
notori difficult build scratch done
growth bank oxymoron past decad grown tangibl book
valu per share dividend compound-annual-growth-rate strong growth
compani especi bank inde bank growth usual driven loan
growth rapid loan growth typic regard red flag bank analyst
usual accompani eventu weak credit qualiti credit qualiti
record except sinc cumul sic net loan loss
loan averag annual net loan loss sinc
one-seventh averag bank
rais price target share current trade
ep estim new price target equat ep
estim versu previous deserv premium high-
qualiti smid-cap bank exampl cullen/frost banker buy high-
qualiti bank major surviv bank texa trade price-to-earnings
premium warrant cullen frost grown tangibl book valu per share
dividend compound-annual-growth-rate past decad versu
averag net loan loss annual period versu
substanti premium clearli warrant view
reiter buy rate next four quarter expect stock price
appreci price target dividend yield
result estim total return nearli
click full note
delmar host kol opinion leader event year sno societi
neuro-oncolog confer weekend highlight result
compani two on-going studi glioblastoma gbm well
discuss clinic landscap five expert space
data view actual quit good dmpi share sell-off
yesterday believ may miscommun
press releas later correct compani two key piec data
first line set median improv month vs
first iter press releas
recurr set median os improv month vs
first iter press releas
mean gbm particularli unmethyl
popul improv month signific
first press releas data show would impli someth far
less suggest efficaci around may
highlight data sno key take-away data thu
far continu compel next step full-data readout
frontlin recurr gbm studi adjuv follow
importantli compani fund reach mileston given
data shown sno activ around dmpi share would buyer
weak
come sno confer two area focu kol
say data
kol panel member includ four delmar scientif advisori board well
lead investig on-going trial frontlin gbm note physician
scientist panel extens experi gbm space includ one
involv sever high-profil studi checkmat studi
gbm
blood-brain barrier unlik mani drug assess set
get brain hour post-infus high csf
cerebrospin fluid plasma
mechan action moa pre-clin studi shown anti-tumor
activ regardless management promot methyl statu distinct moa
provid rational evalu unmethyl popul
turn chemotherapeut drug doesnt need sexi work
one kol point date checkpoint car-t adc novel
therapeut shown clinic benefit gbm contrast cytotox
treatment approach benefit patient histor set could
potenti move bar diseas
safeti intent-to-treat dose myelosuppress
common advers event seen may superior safeti profil
lomustin often use salvag set accord kol
physician would recept drug use maintain dose-
intens exposur elicit anti-tumor effect lomustin difficult drug
elderli patient toler given diminish bone marrow reserv
approv drug although random pivot studi would requir kol
suggest agent demonstr surviv vs expect
month standard care soc worth pursu given lack
treatment choic gbm sever decad
updat trial result remind delmar two open-label non-
random clinic studi underway gbm patient mgmt-
unmethyl promot group make gbm patient
prognosi wors patient soc temozolomid tmz effect
mgmt-methyl promot
china studi patient enrol median progression-
free surviv patient dose evalu
month compar histor month soc tmz posit far
view small number translat improv month
improv
recurr gbm md anderson patient enrol
plan dose
evalu group primari endpoint median overal surviv
mo group saw mo month increas histor
refer month seen lomustin
adjuv gbm md anderson group evalu
follow patient progress recurr set initi
juli five patient enrol
click full note
strong driven robust mortgag bank activ
septemb ep versu estim maxim
firm cover fsfg in-line earn includ strong mortgag
bank activ mortgag rate fell team hire april gain
maintain price target equat vs previous
new ep estim line
result summari novemb post-clos fsfg report ep
versu restat result compar
restat includ net interest margin nim strong
gain sale sba loan mention robust mortgag bank
activity/gain substanti incent compens drove total
expens expect stabl nim lower level sba gain
mortgag bank gain incent compens
mortgag bank oper drove stronger profit team yield
result april fsfg hire team mortgag bank profession
origin sell conform mortgag mortgag bank oper
near break-even oper becam profit
oper contribut ep oper contribut
expect materi lower contribut mortgag origin volum
remain elev less robust
regard credit qualiti concern view fsfg credit qualiti
remain solid non-performing asset npa loan unchang
loan loss reserv equal npa vs net
charge-off averag loan vs
lower ep estim base new
ep estim slower ramp page
updat earn model ep estim assum mortgag
origin volum slow materi level
maintain price target fsfg share current trade new
ep estim price target equat new ep
estim previous prior ep estim line
reiter buy rate next four quarter expect stock price
appreci price target dividend yield
result estim total return
click full note
speed bump refresh focu revenu growth
cytosorb announc follow blind interim mileston review
data refresh studi data monitor committe dmc
recommend temporari paus patient enrol receiv
addit data analysi clinic data trial
includ current protocol
assumpt heart surgeri cytosorb us approv
slight delay refresh trial impact
valuat assumpt given consid alreadi conserv
timelin us key driver compani remain revenu growth
cytosorb europ continu grow y/i chang estim
reiter buy rate
us refresh studi paus patient enrol due recommend
dmc requir addit data patient alreadi complet
trial compani also appoint new contract research organ cro work
trial addit inform request dmc intend improv
safeti endpoint monitor collect patient complet
trial thu far enrol paus focu effici data collect
compani anticip file protocol amend fda
recal pivot random multi-cent blind studi evalu cytosorb
effect reduc acut kidney injuri aki patient undergo elect non-
emerg open-heart surgeri either valv replac aortic reconstruct
hypotherm cardiac arrest trial activ site target
patient current enrol date interim analysi expect
trial complet expect pma file later year
note trial delay sever time given temporari paus
enrol timelin may push
refresh paus focu shift toward tisorb studi potenti
expans remov anti-thrombot drug prior surgeri open label studi
target enrol patient undergo emerg open heart
surgeri within hour last dose ticagrelor trial expect complet
time-frame compani intend pursu label expans prior data
on-going trial submit result complet retrospect studi
retrospect studi patient ticagrelor rivaroxaban cytosorb
integr procedur use control cytosorb
group patient requir rethoracotomi chest crack compar
control addit hour drainag reduc
bleed complic reduc cytosorb patient requir red
blood cell transfus vs control vs platelet
acut kidney injuri aki acut kidney injuri abrupt loss kidney function
common disord world-wide develop develop nation occur
peopl neg affect patient morbid us
estim case seen annual importantli cardiac-surgeri patient
affect aki accordingli develop implement effect strategi
elimin prevent death aki critic data address
epidemiolog caus aki resourc diagnos manag condit
also limit end cytosorb could potenti reduc post-op
aki way purifi adsorb cytokin inflammatori mediat
occur complex cardiac surgeri
click full note
medicin compani goe novarti activ
turn posit adcom amarin amrn nr vascepa
activ around cardiovascular space continu novarti
nv nr announc acquisit medicin compani mdco nr
center around inclisiran semi-annual inject sirna target
reduc cholesterol -c patient adequ treat
statin news view bode well cardiovascular cv
space also space
inclisiran semi-annual
inject may overcom commerci
challeng repatha praluent import though come back
need lower ldl-c cardiovascular diseas risk beyond
statin even statin mani patient reach
target threshold ldl-c mg/dl non-adher remain
despit make one largest drug class medicin statin
complet pictur cv modal need fulli address
cv diseas ultim cholesterol like part pictur
triglycerid thu anoth part see vascepa
view earlier stage develop may case
potenti best-in-class consid demonstr
improv efficaci vs vascepa uniqu effect
express lower vs vascepa bottom line may
complimentari statin also sirna inclisiran antibodi
inhibit reduc cholesterol proprotein convertas subtilisin/kexin
type enzym reduc number receptor cell
inhibit increas metabol reduc cholesterol level
blood stream drug approv target
nr repatha sanofi sni nr praluent despit market sinc
mab face commerci difficulti around price question
around cost-effect launch price biweekly/monthli inject
administr inconveni patient physician number price
reduct rebat approach incentiv payer reimburs repatha seem
pull ahead gener sale inclisiran may abl
differenti though mechan rna interfer enabl semi-
annual dose though novarti seem believ prefer modal
enough unlock predict blockbust potenti inhibit space
challeng still remain includ secur reimburs whether physician
opt inject therapi even semi-annu mdco current run long
term outcom studi evalu reduct cardiac
risk could also help prove valu proposit similar reduce-
studi
cholesterol one part pictur like
complementari praluent repatha larg use patient cholesterol
adequ control statin also segment target inclisiran
ldl-c long establish target therapi reduc risk cv diseas
cvd triglycerid rel overlook recent result
reduce-it trial demonstr rel risk reduct major advers
cardiac event mace provid hard evid random control trial
link triglycerid reduct improv cv outcom triglycerid ldl-c
demonstr play role cvd substanti number patient
neither adequ control statin alon like go requir
combin differ approach minim cv risk
like play role view
next event space vascepa pdufa recal adcom
alreadi posit interest us import epa exposur epa
respons reduct cv risk unanim result adcom
valid epa exposur like respons reduct cv event
risk posit demonstr superior bioavail
higher epa auc steadi state cmax compar vascepa epa-e
prior
click full note
custom board linear dna could follow
also watch ctc platform
apdn report develop custom board evalu
linear dna platform key take-away referenc upgrad
note apdn approach take dna plasmid linear
could disrupt nucleic acid-target space
apdn platform attract companies/group lead effort car-t
gene therapi vaccin diagnost rna therapi latter space
recent subject media headlin novarti nv nr
announc acquir medicin compani mdco nr
sirna therapi inclisiran
earli stage apdn collabor evalu
technolog earli result encourag collabor
could potenti expand time addit apdn plan expand client
base collabor across space overal see compani
potenti tangenti play nucleic acid space
circul tumor cell assay much focu
tag linear dna collabor also point
apdn potenti disrupt ctc assay oppos approach
mainli biomarker-driven apdn assay captur
metastat potenti well engag white blood cell approach
view could emerg stand-alone assay complimentari assay
space
take dna linear abil produc larg quantiti linear dna gram scale
use gener therapeut engin cell gene therapi
vaccin rnai standard space circular dna
limit term quantiti produc well factor amplicon
length packag size limit toxin linear approach could also mitig
need use drug select gene use viral vector deliv genet
materi pose risk apdn current collabor make
linear dna serv contract research organ cro signific
revenu gener yet cost apdn essenti de minimi real upsid
view realli question compani come board
develop therapeut use apdn contract manufactur organ
compani opt move forward drug candid apdn default becom
embed process much like buy integr
cell media cell/gen therapi develop
circul tumor cell assay addit detect circul tumor dna ctdna
use analyz mutat detect circul tumor
cell potenti addit valu diagnost power liquid biopsi
includ ctc signific august linearx acquir asset ip
vitatex platform function isol invas platform lend
diagnost prognost therapeut platform function extraversion/
introvers assay detect cell blood metastatis-initi mean
tumor cell metastas need digest way
primari tumor site extracellular matrix extravers get
blood lymphat digest way circul new
site intravers apdn assay use cell adhes matrix
place invas cell capabl metastasi digest matrix
cross side assay may also come white blood cell
attach apdn acquir antigen cell engag
inform develop new therapeut
click full note
zimhi get downgrad share hold
adami announc receiv complet respons letter
fda regard nda zimhi naloxon share
addit cash low report
downgrad admp share hold buy remov prior
price target await clariti path forward compani
question pertain chemistri manufactur control
clinic safeti efficaci issu rais
model chang model updat result adami report
revenu quarter net loss compani end
period cash announc morn zimhi naloxon receiv
remov potenti revenu model
factor risk adjust downgrad admp share hold
buy remov prior price target await clariti path forward
compani
product zimhi adami countersuit settl announc
pdufa set pass earn call
announc morn compani receiv
relat chemistri manufactur control clear time
type type month compani plan expand test
alreadi provid fda satisfi item await
clariti addit given compani cash balanc current
burn rate adami like go need rais capit like distress
click full note
maxim analyst coverag univers
sector coverag
care well
industri util
receiv full disclosur compani maxim group coverag mention report pleas send
